Can you still get infected after receiving the hepatitis B vaccine?
May 22, 2022
Source: Cainiu Health
Dr. Jiang Weimin
Introduction
Vaccination can induce the production of hepatitis B antibodies, providing effective protection against hepatitis B virus (HBV) infection. However, not everyone develops detectable antibodies after receiving the hepatitis B vaccine; individuals with compromised immunity may fail to produce antibodies and remain susceptible to HBV infection. Therefore, after completing the hepatitis B vaccination series, it is recommended to undergo follow-up testing for the “hepatitis B serological panel” (commonly referred to as the “two pairs and a half” test) to confirm whether protective antibodies have been generated. A high titer of hepatitis B surface antibody (anti-HBs) indicates robust immune protection.
In daily life, some individuals who have received the hepatitis B vaccine harbor concerns about whether they remain susceptible to hepatitis B infection despite vaccination—causing them considerable anxiety and prompting questions about the need for re-vaccination. So, can one still contract hepatitis B after receiving the hepatitis B vaccine?
Can hepatitis B infection still occur after vaccination?
Vaccination stimulates the production of hepatitis B surface antibodies (anti-HBs), thereby providing effective protection against hepatitis B virus (HBV) infection. However, not everyone develops protective antibody levels following vaccination. Individuals with compromised immune function may fail to mount an adequate antibody response and thus remain susceptible to HBV infection.
Therefore, after completing the hepatitis B vaccination series, it is recommended to undergo follow-up testing for the “hepatitis B serological panel” (commonly referred to as the “two-and-a-half pairs” test) to confirm whether protective anti-HBs antibodies have developed. A high anti-HBs titer indicates robust immunity. If the antibody titer is low or undetectable—signifying minimal or no protection—booster vaccination is advised to elicit a new, protective antibody response. Moreover, even in individuals who initially develop antibodies, antibody levels may gradually decline or become undetectable over time, especially with advancing age, potentially increasing susceptibility to HBV infection. Hence, periodic monitoring of the hepatitis B serological panel—ideally every three to five years—is recommended to assess anti-HBs titers. Should a significant decline be observed, revaccination should be considered.
Additionally, if symptoms suggestive of hepatitis B infection arise, prompt medical evaluation at a healthcare facility is essential, and management should be conducted under the guidance of a qualified physician. We hope this information proves helpful to you!
